Amarin Calls Activist Investor, Largest Shareholder Sarissa’s Statement ‘Inaccurate, Misleading’

• Amarin Corporation Plc (NASDAQ: AMRN) reacted to its largest shareholder, Sarissa Capital Management, which said Amarin’s recent board refreshment put “no shareholder representatives on the board.”

• Sarissa said in its statement Wednesday that Amarin “has repeatedly overpromised and underdelivered,” with the European launch being delayed and reimbursement in Germany appearing to be imperiled.

• Amarin described Sarissa’s published statement as “inaccurate and misleading.”

• The drugmaker said its board refreshment process was “comprehensive, independent and transparent,” and Sarissa’s candidates “are not qualified” compared with recently appointed board members.

• Amarin says the board refreshment process has been comprehensive, independent, and transparent.

• The company also says Sarissa’s intervention will lead to distraction, disruption, and destruction of future value.

• Earlier this month, for Q4 and FY22, Amarin forecasted revenues of $88-$90 million and $367-$369 million, respectively, reflecting ongoing stabilization of the U.S. business for Vascepa (icosapent ethyl).

• Amarin ended 2022 with approximately $310 million in cash and investments, with a positive cash flow of approximately $4 million in the fourth quarter of 2022.

• Price Action: AMRN shares are flat at $1.85 on the last check Thursday.

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.